Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance of icalcaprant in healthy males
NCT07219017Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of icalcaprant in focal segmental glomerulosclerosis (FSGS), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at 32 days, Number of Participants with Abnormal Change from Baseline in Vital Signs at 15 days and 10 more. Started Oct 2025; status: completed.
02
Drugs
icalcaprant
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT07219017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219017.